RaySearch Laboratories Reports Interim Earnings for Q2 2025 Amid Significant Developments
RaySearch Laboratories Reports Interim Earnings for Q2 2025 Amid Significant Developments
RaySearch Laboratories AB (publ), a leading medical technology firm renowned for its innovative software solutions focused on improving cancer treatment, has unveiled its interim financial report for the second quarter of 2025. This period was notable for both substantial achievements and financial performance, signaling the company's ongoing commitment to enhancing medical technologies that support oncology care.
Financial Overview
During the second quarter of April through June 2025, RaySearch reported an order intake of SEK 241.2 million, a decrease from SEK 290.3 million in the previous quarter. Despite this decrease in orders, the total net sales reached SEK 304.9 million, slightly down from SEK 318.9 million in the prior corresponding period. The company’s operating profit for this quarter was listed at SEK 36.4 million, a significant drop from SEK 79.3 million reported previously.
The profit after tax amounted to SEK 30.8 million, indicating a decrease from last year’s figure of SEK 61.4 million. The earnings per share, both before and after dilution, were recorded at SEK 0.90, down from SEK 1.79 earlier.
In terms of cash flow from operating activities, the figure stood at SEK 70.6 million, down from SEK 154.6 million in the previous year. Moreover, the order backlog at the end of the reporting period reached SEK 1,665.3 million, compared to SEK 1,790.5 million at the end of Q2 last year.
For the first half of 2025, the company reported a pickup in order intake amounting to SEK 650.8 million, which is an increase from SEK 528.8 million from the same period in 2024. Total net sales were SEK 636.6 million, up from SEK 576.1 million, showcasing strong growth momentum for the firm across the first six months of the year.
Significant Advances in Technology
Key milestones were achieved in this reporting period. Notably, Odense University Hospital in Denmark placed an order to enhance automation capabilities through RayStation’s treatment planning system. Additionally, the launch of RayStation v2025 in May introduced advanced features such as machine learning-driven automated treatment planning using the ECHO algorithm. This version also expanded support for treatment plans enabling patients to be treated in an upright position.
Another major event came from the Royal Marsden in the UK, where the clinic became the first globally to utilize the new adaptive re-planning module in RayStation during online adaptive radiotherapy. Moreover, RaySearch marked a historic milestone at Helsinki University Hospital, conducting the first accelerator-based BNCT treatments in Europe.
In June, the launch of RayCare v2025 took place, which brought forth powerful functionality enhancements to streamline clinical workflows, improve data management, and advance interoperability throughout the treatment continuum.
Post-Report Period Updates
After the reporting period, RaySearch entered into a strategic partnership with Radiology Oncology Systems, Inc. (ROS), focusing on integrating refurbished linear accelerators with advanced software solutions. Additionally, a new cancer center selected RayCare and RayStation, underlining the increasing adoption of RaySearch's solutions in critical healthcare delivery.
The executives of RaySearch, including CEO Johan Löf and CFO Nina Grönberg, shared plans to present the interim report during a webcast, thus ensuring transparency and providing stakeholders with the opportunity to engage with the company's performance and future outlook.
As RaySearch Laboratories continues to innovate and evolve within the oncology field, the company remains steadfast in its mission to enhance cancer treatment methods worldwide. Further information regarding their journey and offerings can be accessed at raysearchlabs.com.
This report reflects not only the challenges faced in the current market but also the incredible advancements made to improve cancer care, highlighting RaySearch's position at the forefront of the medical software landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.